To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

A pharmacokinetic and dos… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants

Journal article
Authors Chatarina Löfqvist
Aimon Niklasson
Eva Engström
L. E. Friberg
C. Camacho-Hubner
D. Ley
J. Borg
L. E. Smith
Ann Hellström
Published in Pediatric Research
Volume 65
Issue 5
Pages 574-9
ISSN 1530-0447
Publication year 2009
Published at Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
Institute of Clinical Sciences
Pages 574-9
Language en
Keywords Birth Weight, Female, Gestational Age, Half-Life, Humans, Infant, Newborn, *Infant, Premature, Infusions, Intravenous, Insulin-Like Growth Factor Binding Proteins/*administration &, dosage/adverse effects/blood/*pharmacokinetics, Insulin-Like Growth Factor I/*administration & dosage/adverse, effects/*pharmacokinetics, Male, Recombinant Proteins/administration & dosage/pharmacokinetics
Subject categories Medical and Health Sciences


In preterm infants, low levels of insulin like growth factor 1 (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics of i.v. administered rhIGF-I with its binding protein 3 (rhIGFBP-3) to preterm infants. At 3 d chronological age, an i.v. 3 h infusion of rhIGF-I/rhIGFBP-3 was administered followed by serial measurements of IGF-I and IGFBP-3. Infants were evaluated for physiologic safety measurements. The individual dose of rhIGF-I ranged from 1 to 12 microg/kg. The study was conducted at Queen Silvia Children's Hospital, Gothenburg, Sweden, between January and November 2007. Five patients (3 F) with mean (range) post menstrual age 27 wk (26-29) and birth weight 1022 g (810-1310) participated. IGF-I and IGFBP-3 levels before infusion were median (range) 18 (12-28) and 771 (651-1047) ng/mL, respectively. Immediately after study drug infusion, serum IGF-I and IGFBP-3 levels were 38 (25-59) and 838 (754-1182) ng/mL, respectively. Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively. Blood glucose, insulin, sodium, potassium, and physiologic safety measures were within normal ranges. The rhIGF-I/rhIGFBP-3 equimolar proportion was effective in increasing serum IGF-I levels and administration under these study conditions was safe and well tolerated.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?